Clinical Trial Update: Acelarin First Line Randomised Pancreatic Study [Phase 2, Phase 3]

View source ↗

Summary

A randomized study of Acelarin in first-line pancreatic cancer is currently suspended, with both Phase 2 and Phase 3 components reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Acinar Carcinoma
• Pancreatic Neoplasms

Drugs mentioned

• Acelarin (nitrosourea prodrug? (Note: Acelarin is a gemcitabine prodrug known as N4-palmitoyl gemcitabine? If uncertain, leave generic_name as null))

Snippet

Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust | Conditions: Pancreatic Acinar Carcinoma, Pancreatic Neoplasms | Phase 2, Phase 3 | Status: SUSPENDED